New pharmaceutical products face many potential hurdles to commercial success including regulatory approval, national and regional market access, and physician and patient acceptance and uptake, to name a few. Each stage of the development cycle involves an ever-widening group of stakeholders. Securing the buy-in of these influential external stakeholders requires pharmaceutical companies to look inward and encourage cross-functional collaboration and the ability to engage early, and often, along the path to launch and beyond. To read more, click the link below.
100 days. 14 executive orders. Some bold healthcare policies.
In this CRA Insights, we assess the actions and impact of the second Trump Administration during the first 100 days that directly affect healthcare policy,...